Marc de Garidel
Marc de Garidel | |
|---|---|
| Born | 1956 (age 69–70) Aix-en-Provence, France |
| Education | École Spéciale des Travaux Publics Thunderbird School of Global Management Harvard Business School |
| Occupation | Businessman |
| Known for | Former CEO, Ipsen (2010-16) |
| Title | CEO Abivax |
| Term | 2023- |
| Honours |  Knight Legion of Honour (2008) |
Marc de Garidel is a French Biotech Entrepreneur. He is the CEO of Abivax, a French clinical-stage, publicly traded biotechnology company (ABVX at Euronext Paris and Nasdaq Global Market), which he joined in May 2023.
He is also the non-executive chairman of the pharmaceutical company Ipsen since 2010. He is on the board of Claris Bio, a Harvard Ophthalmology spin-off.
Education
Marc de Garidel has a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, has a Master's in International Management (MIM) from Thunderbird Global School Management in Glendale, Arizona, US, and an executive MBA from Harvard Business School in Boston, Boston, Massachusetts.[citation needed]
Career
In 1983, he started his career at Eli Lilly and Company, where he worked in France, the United States and Germany.[citation needed]
In 1995, he joined Amgen as vice president of finance and treasury for Europe.[citation needed] In 1998, he became vice president, corporate controller and chief accounting officer of Amgen.[citation needed] In 2000, he became vice president and general manager for France, in charge of Amgen France.[citation needed] In 2006, he became vice president for Southwestern Europe, including France, Spain, Belgium and Portugal. From 2007 to 2010, he served as vice president for Southern Europe, the Middle East, Asia and Latin America at Amgen.[citation needed]
He was chairman and chief executive officer of Ipsen from November 2010 to July 2016.[citation needed]
He was also president and spokesperson for G5 santé, a lobbying group for French pharmaceutical companies, including BioMérieux, Guerbet, Ipsen, the Laboratoire français du Fractionnement et des Biotechnologies, Laboratoires Pierre Fabre, Sanofi, Stallergenes and Laboratoires Théa.[citation needed]
In early 2018, de Garidel joined Corvidia Therapeutics, a biotech company based in Waltham, Massachusetts. In April 2018, he raised a $60M series B round led by Venrock and other top-tier US and European venture capital funds. In June 2020, after its lead asset, Ziltivekimab, was near completion of its phase 2b program, the company was acquired for $2.1B, including an upfront of $725M by Novo Nordisk in one of the largest transaction of the biotech sector in the midst of the Covid-19 pandemic.[citation needed]
From July 2021 through February 2023, de Garidel served as CEO of CinCor Pharma where he led the successful sale of the company for up to $1.8B, subject to the achievement of certain milestones, to AstraZeneca in February 2023.[citation needed]
Distinctions
France: Knight of the Legion of Honour (2008)[1]
Bibliography
- La Société du Médicament (2006)
References
- ^ "Ordre de la Légion d'honneur - Nominations, promotions et élévations du 11-07-2008". www.france-phaleristique.com. Retrieved 2022-12-13.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.